由西北大学开发的由林业发展局核准的新的丙型肝炎测试能够100%精确地进行同一天的诊断和治疗。 A new FDA-approved hepatitis C test, developed by Northwestern University, enables same-day diagnosis and treatment with 100% accuracy.

美国西北大学开发的15分钟C型肝炎新检测,FDA于2024年6月批准,可在一次诊所访问期间在同一天进行诊断和治疗. A new 15-minute hepatitis C test developed by Northwestern University, approved by the FDA in June 2024, enables same-day diagnosis and treatment during a single clinic visit. 使用原为COVID-19设计的重新定位的护理点装置,试验速度比以前的快速测试快75%,并且已经以100%的精确度独立验证了实验室结果。 Using a repurposed point-of-care device originally designed for COVID-19, the test is up to 75% faster than previous rapid tests and has been independently validated with 100% accuracy in matching lab results. 创新消除了从送样本到场外实验室的延误,有可能提高治疗率和支持到2030年消除丙型肝炎的全球努力。 The innovation eliminates delays from sending samples to off-site labs, potentially boosting treatment rates and supporting global efforts to eliminate hepatitis C by 2030. 调查结果于2025年12月10日在《传染病期刊》上公布。 The findings were published on December 10, 2025, in The Journal of Infectious Diseases.